

MELANOTAN II

TANNING AND FAT LOSS

MOLECULAR FORMULA $C^{50}H^{69}N^{15}O^9$

MOLECULAR WEIGHT 1024.2

SEQUENCE Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH₂(cyclic 2-7)

PROTOCOL



CONTENT & POTENCY

INJECTABLE: 5ml at 2000mcg/ml : ready-to-inject subcutaneously



SUGGESTED DOSAGE

INJECTABLE: 0.15ml daily for 1 - 2 weeks then 0.25mL twice weekly for maintenance.

DESCRIPTION

Melanotan I and Melanotan II are both analogs of the peptide hormone α -melanocyte stimulating hormone (α -MSH) that induces skin tanning. Like its predecessor, Melanotan I, MT 2 plays a role in stimulating melanogenesis and thus provides a protective mechanism against UV rays since under its actions melanocytes are able to increase production and secretion of the hormone melanin. Scientists have also noticed that MT 2 had a positive effect on libido due to its aphrodisiac properties. Additionally, MT 2 exhibits a mild positive fat-mobilizing effect. Melanotan I is an FDA approved drug under the brand name Scenesse. Scenesse is most commonly used to treat patients that have an intolerance to light.

CLINICAL RESEARCH



Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Source: College of Medicine, Pharmacology Department, University of Arizona, Tucson, USA.



Abstract: A pilot phase I study was conducted with a cyclic heptapeptide analog of α -melanocyte stimulating hormone (α -MSH). The lactam-bridged molecule, called Melanotan-II (MT-II), has the structure Ac-Nle⁴-Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰ α -MSH₄₋₁₀-NH₂ (MT-II) and has superpotent melanotropic activity in vitro. A single-blind, alternating day (saline or MT-II), placebo-controlled trial was conducted in 3 normal male volunteers at the starting dose of 0.01 mg/kg of MT-II. Subcutaneous injections of MT-II or saline were given daily (Monday-Friday) for 2 consecutive weeks. Two subjects were escalated by 0.005 mg/kg increments to 0.03 mg/kg and one to 0.025 mg/kg. The 0.03 mg/kg dose produced Grade II somnolence and fatigue in one of two subjects (WHO standards). Mild nausea, not requiring antiemetic treatment, was reported at most MT-II

dose levels. A stretching and yawning complex appeared to correlate with the onset of spontaneous, Penile erections which were intermittently experienced for 1-5 hours after MT-II dosing, depending on the MT-II dose. Two subjects had increased pigmentation in the face, upper body and buttock, as measured by quantitative reflectance and by visual perception 1 week after MT-II dosing ended. These results demonstrate that MT-II has tanning activity in humans given only 5 low doses every other day by subcutaneous injection. The recommended single MTII dose for future Phase I studies is 0.025 mg/kg/day.

"This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."



ReNEW LifeRX